{
    "clinical_study": {
        "@rank": "131198", 
        "acronym": "SHIFT-2", 
        "arm_group": {
            "arm_group_label": "Aflibercept", 
            "arm_group_type": "Experimental", 
            "description": "Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks"
        }, 
        "brief_summary": {
            "textblock": "SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in\n      patients with wet age related macular degeneration who have incomplete response with monthly\n      ranibizumab treatment."
        }, 
        "brief_title": "Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Monthly Ranibizumab Injections", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Age Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Note: Subjects must meet all of the following inclusion criteria to be eligible for\n        enrollment into the study\n\n          1. Age >50 years\n\n          2. Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD\n             including juxtafoveal lesions that affect the fovea as evidenced by Fluorescein\n             Angiography in the study eye\n\n          3. Presence of intra or sub retinal fluid on SDOCT\n\n          4. Current treatment with monthly(q31 +/- 3 days)ranibizumab started between 3 to 9\n             months before Baseline (Week 0), having received at least 3 consecutive monthly\n             ranibizumab injections in the previous 9 months, with no interruptions in ranibizumab\n             IVI monthly {31 \u00b1 3 days prior to Baseline (Week 0)}\n\n          5. ETDRS BCVA between 20/40 and 20/320 (letter score of 73 to 25)\n\n        Exclusion Criteria:\n\n        Subjects presenting with any of the following will not be included in the study:\n\n          1. Presence of purely serous pigment epithelial detachment\n\n          2. Any scarring or fibrosis involving the center of the fovea\n\n          3. Prior ocular or systemic treatment/surgery for wet AMD other than ranibizumab IVI\n             monthly (in study eye)\n\n          4. Prior prn or treat and extend treatment with ranibizumab IVI monthly between 3 to 9\n             months before Baseline (Week 0)\n\n          5. Prior treatment with systemic anti-VEGF therapy within the last 6 months\n\n          6. History of vitreous hemorrhage within the last 6 months\n\n          7. Prior vitrectomy in the study eye\n\n          8. History of retinal detachment in study eye\n\n          9. History of macular hole of stage 2 and above in the study eye\n\n         10. Presence of retinal pigment epithelial tears or rips involving the macula in the\n             study eye.\n\n         11. Any intraocular or periocular surgery/invasive procedure during the previous 6 months\n             except lid surgery\n\n         12. Prior trabeculectomy or other filtration surgery in the study eye\n\n         13. Uncontrolled glaucoma (\u2265 25mmHg despite treatment with anti-glaucoma medications).\n\n         14. Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a\n             result of a yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye.\n\n         15. Scheduled for intraocular surgery during the study period\n\n         16. Concurrent retinal disease (i.e. diabetic retinopathy, retinal vein occlusion,\n             retinal detachment, uveitis)\n\n         17. History of ocular or periocular infection/inflammation within the last 4 weeks of\n             screening\n\n         18. Pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "51 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002377", 
            "org_study_id": "01"
        }, 
        "intervention": {
            "arm_group_label": "Aflibercept", 
            "description": "Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks", 
            "intervention_name": "Aflibercept", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Age Related Macular Degeneration, wet", 
            "aflibercept"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Thomas Sheidow", 
                    "phone": "(519) 685-8500"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4V2"
                    }, 
                    "name": "Ivey Eye Institute"
                }, 
                "investigator": {
                    "last_name": "Thomas Sheidow", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5B1W8"
                    }, 
                    "name": "St. Michael's Hospital"
                }, 
                "investigator": {
                    "last_name": "Rajeev Muni, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Brent", 
                    "phone": "(416) 603-5444"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5T 2S8"
                    }, 
                    "name": "Toronto Western Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Brent", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "The SHIFT-2 Study: Use of Intravitreal Aflibercept in Wet Age Related Macular Degeneration (AMD) Patients With an Incomplete Response to Monthly Ranibizumab Injections", 
        "overall_official": [
            {
                "affiliation": "St. Michael's Hospital, Toronto", 
                "last_name": "Michael H Brent, MD, FRCSC", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "St. Michael's Hospital, Toronto", 
                "last_name": "Rajeev Muni, MD, FRCSC", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "'OCT defined success' defined by no presence of intra or sub retinal fluid on SDOCT", 
            "safety_issue": "No", 
            "time_frame": "After 12 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002377"
        }, 
        "responsible_party": {
            "investigator_affiliation": "St. Michael's Hospital, Toronto", 
            "investigator_full_name": "Michael Brent", 
            "investigator_title": "Affiliate Scientist", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "'OCT defined success' defined by no presence of intra or sub retinal fluid on SDOCT", 
                "safety_issue": "No", 
                "time_frame": "16 weeks after treatment"
            }, 
            {
                "measure": "Change in central retinal thickness (CRT)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 12, 16, and 48"
            }, 
            {
                "measure": "Change in Early Treatment Diabetic Retinopathy Study best-corrected visual acuity", 
                "safety_issue": "No", 
                "time_frame": "Week 12, 16, and 48"
            }
        ], 
        "source": "St. Michael's Hospital, Toronto", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Michael Brent", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}